🔗 Share this article

As the United States undertakes historic changes to its vaccine recommendations, an unexpected name appears somewhat surprisingly: Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots in the pandemic and has concentrated on possible fatalities after COVID-19 vaccination in her brief position at the FDA.

Planned Shifts to Pediatric Vaccine Schedule

Health officials planned to reveal major changes to the childhood vaccine schedule in December, synchronizing the US with the Danish vaccine program, according to reports – a significant shift that would put the US out of step with a large portion of the world with no evidence for improved outcomes. The planned update has been delayed until the coming year.

In place of the top vaccines chief, Høeg is scheduled to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the drug and vaccine divisions as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon reevaluating already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending specific pediatric immunization guidelines in the US so as to align more in line with the Danish model, a society with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on immunizations – usually the responsibility of Prasad, head of the FDA’s CBER – rather than drug regulation.

Doubts Over Qualifications

The appointee has little discernible experience in pharmaceutical research, approval processes or leadership, which has been typical for former heads of the biologics center. She has worked at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a sizeable institution. She lacks background in drug approvals.”

Previous commissioners of the center would “understand regulatory frameworks and the underlying principles of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that former directors who ran CBER have had.”

This division has an enormous workload at the agency, Woodcock pointed out.

“Everybody just zeroes in on the new drug program, but the off-patent medication office approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these must be looked after,” she said. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant management aspect to the position, which manages more than 5,000 employees. “It’s a huge leadership role, if you perform it correctly,” the former official said.

Official Statement and Disputed Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this selection represents greater collaboration among agency officials on immunizations, a spokesperson responded that the “inquiries are based on inaccurate premises”.

“Her resume matches the duties of her role,” the representative explained, noting the time Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a disputed expedited drug-approval program that reportedly troubled her preceding directors. “By what process are these drugs being chosen for this expedited pathway? Who is making the decisions?” Dr. Howard questioned. “There is a lot of confidentiality going on at the agency right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards laxer rules of most medications, except for vaccines.”

Established History on Vaccines

Concerning vaccines, Høeg has a clearer, if problematic, history, critics said. She authored a analysis using unconfirmed volunteer-provided data to assess the frequency of myocarditis after Covid vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the current administration encompassed changing guidelines for recently developed shots and halting “optional” immunizations, she remarked after the election on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of excluding adolescent males from receiving COVID-19 vaccines.

“She’s an thorough dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the science in a very deceptive, dishonest way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|